 "Biocon likely to channelise investments towards non-insulin biologics")
The Biocon stock continues to outperform its pharma peers, gaining 20 per cent since its September lows. The stock added 3 per cent to its returns on Wednesday after a decent December quarter performance, ramp-up of certain products, and fresh launches in the biologics space. The growing small molecules business, rising investments, and regulatory go-ahead for its plants are the additional triggers.
The company’s December quarter growth was led by the biologics segment, which reported a 31 per cent growth year-on-year (YoY). The segment accounts for a third of its sales. The rising sales of key biosimilars, such as Ogivri (a
